Hospira Receives Favourable Court Decision On Eloxatin

Hospira has announced that the US District Court for New Jersey, has granted summary judgment of non-infringement in Hospira’ favour, with regard to Sanofi Aventis’ chemotherapy medication, Eloxatin. The company has tentative approval from FDA for its generic version of the product.

Hospira expects full FDA approval shortly.

Hospira’ version of Eloxatin, which goes by the generic name – oxaliplatin injection, would be one of the first generic versions available in the US to come in solution form.

Joshua Gordon, Vice President of Specialty Pharmaceuticals, Hospira, said: We are extremely pleased with the court’s ruling. The launch of Hospira’s oxaliplatin injection will provide a high-quality, lower-cost alternative to patients, and is another example of Hospira working to meet patient and caregiver needs in the fast-growing oncology market.